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ABSTRACT
In 2005 India changed its pharmaceutical and innovation
policy that facilitated a dramatic increase in international
clinical trials involving study sites in India. This policy shift
was surrounded by controversies; civil society organisations
(CSOs) criticised the Indian government for promoting the
commercialisation of pharmaceutical research and
development. Health social movements in India fought for
social justice through collective action, and engaged in
normative reasoning of the beneﬁts, burdens and equality
of research. They lobbied to protect trial participants from
structural violence that occurred especially in the ﬁrst 5–6
years of the new policy. CSOs played a major role in the
introduction of new regulations in 2013, which accelerated
a decline in the number of global trials carried out in India.
This activism applied interpretations of global social justice
as key ideas in mobilisation, eventually helping to
institutionalise stricter ethical regulation on a national level.
Like government and industry, activists believed in
randomised controlled trials and comparison as key
methods for scientiﬁc knowledge production. However,
they had signiﬁcant concerns about the global hierarchies
of commercial pharmaceutical research, and their impact on
the rights of participants and on beneﬁts for India overall.
Pointing to ethical malpractices and lobbying for stricter
ethical regulations, they aimed to ensure justice for
research participants, and developed eﬀective strategies to
increase controls over the business side of clinical research.
KEYWORDS
India; regulation; civil society
organisations; clinical trials;
bioethics; social justice
Introduction
As part of the world-wide oﬀshoring or globalisation of clinical trials that dates
from the 1990s, there has been a dramatic expansion of global clinical trials and
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international contract research organisations (CROs) in India. The number of
trials with Indian sites grew especially after 2005. That year, following the
signing of the World Trade Organization’s (WTO) Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 1995, India
brought its domestic patent laws into line with WTO requirements. This
allowed foreign sponsors to test new drugs in India without fear of copying.
In 2005, India revised its pharmaceutical legislation to match the international
ICH Good Clinical Practice (GCP) Guidelines – which standardises the
conduct of randomised control trials (RCTs) globally and was drawn up by
the pharmaceutical industry (Abraham, 2010; Cooper and Waldby, 2014) – to
enable global phase II and III clinical trials to take place within the country.
Removing restrictions on global trials was part of a national programme
designed to attract trials and encourage Indian pharmaceuticals companies to
shift their Research and Development (R&D) from being almost entirely based
on ‘reverse-engineering’ of existing molecules to carrying out innovative research
on new molecules. Supporters of clinical trials described beneﬁts for India in
terms of foreign exchange earnings and Indian involvement in advanced scientiﬁc
activities. Those promoting India as a trial destination also made bold and, in the
event, exaggerated claims about the likely scale of trial activity in India. The
market research ﬁrm Frost and Sullivan (2012), for example, estimated that
Indian clinical trials business was worth USD $485 million (£282 million) in
2010–2011 and would pass the $1 billion (£594 million) mark by 2016.
Local and international promoters within the pharmaceutical sector stressed
lower expenses for sponsors because of: low Indian salaries; the existence of a
large pool of potential trial participants; and the availability of English-speaking
staﬀ. Carrying out trials could also oﬀer sponsoring companies an opportunity
to build market access by establishing networks of friendly key physicians. Opti-
mistic estimates of the current and future size of the industry helped it to lever-
age assistance from the Government of India: direct funding, its support for
schemes involving collaboration between industry and academia, sharing state
institutions’ infrastructures, and through deregulation itself, for example (Kale
and Little, 2007, pp. 605–606).
The changes brought into play a plethora of new actors in the ﬁeld of clinical
research. Kaushik Sunder Rajan has described India’s emergent CROs, inter-
national sponsors, clinical hospital sites etc. as a form of capacity building
through which India joined the global pharmaceutical industry (Sunder Rajan,
2010). Sariola et al. (2015) call this process ‘Big-Pharmaceuticalisation,’ pointing
to how the pharmaceutical industry is impacting on how, where and on whom
drugs are tested, and changing local industries towards global collaborative and
methodological models.
Civil society groups and voices within mass media contested the economic
policy leading to the increase of international clinical trials in India from the
start. As the number of global trials increased in India (see Table 1), such
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critiques intensiﬁed. In 2013, regulatory reform was demanded by a Parliamen-
tary Committee because of public interest litigation (PIL) by civil society groups
and interventions by the Supreme Court of India. Opponents highlighted appar-
ent human rights abuses and damages suﬀered by trial participants. New rules
introduced by the government’s Central Drugs Standard Control Organisation
(CDSCO) established new criteria for informed consent from participants,
ethics review boards, and the reporting of – and compensation for – cases of
injury or death occurring during a clinical trial. Table 1 shows a decline in the
number of global clinical trials approved per year because of the public critiques
and economic recession in 2010, but in 2013 they dropped considerably. While
the numbers have not increased signiﬁcantly since then, the medium and long-
term impacts and possible changes put in place by the election of a new pro-
industry government remain to be seen.
The national promotion of international RCTs to enhance Indian clinical
research thus masked an under-swell of critique from local researchers and acti-
vists. Members of civil society organisations (CSOs) expressed critical views
regarding the growth of clinical trials in India, but their criticisms were tempered
by realistic expectations of what they believed was achievable. Many of the indi-
viduals we interviewed were themselves conducting public health RCTs, social
interventions or, in the case of one, CRO research. They did not question
medical research methodologies, and many believed that in research, an RCT is
the gold standard for advancing medical knowledge. Despite this, members of
Table 1. Approvals of trials by CDSCO between 2007 and 2017.
Note: All values taken from the running number of the trials approved for that year.
Source: All sources from the CDSCO website for approved clinical trials, accessed 15 September 2016.
2007–2012: http://www.cdsco.nic.in/writereaddata/DCG(I)%20approved%20clinical%20trial%20registered%20in%
20ctri%20website%20(Jan.2013).pdf
2013: http://www.cdsco.nic.in/Forms/list.aspx?lid = 1884
2014: http://www.cdsco.nic.in/Forms/list.aspx?lid = 1883
2015: http://www.cdsco.nic.in/forms/list.aspx?lid = 2093andId = 11
2016 and 2017: http://www.cdsco.nic.in/forms/list.aspx?lid = 2173&Id = 11
Note on the Source: In 2010, the number of approvals by the CDSCO dropped before regulatory restrictions came
into force, which was not until 2013. This ﬁnding is in line with research using data from clinicaltrials.gov, which
also shows a downturn in India around 2010 (Burt et al., 2014). Burt et al relate this drop to ‘reports of ethical
improprieities, activist protests and departure of international collaborations’ (2014, no pagination). In 2013,
with the new regulations, the number drops further, to about a half of the 2011–2012 level.
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Indian CSOs were critical of how clinical trials had come to India and were being
conducted.
This paper seeks to understand these critiques and to link them to the regu-
latory changes by answering the following questions. How did academic medical
researchers, public health researchers and health activists express their opposi-
tion to how clinical trials were being conducted? Why and how did they inter-
vene and lobby for tighter regulation? How far did their concerns help frame the
PIL that led to increasing stringency in the regulation of trials in India?
Our data show that resistance by academic medical researchers, public health
researchers, and health activists in India was primarily against the global hierar-
chies of the pharmaceutical industry that involves the commercialisation of
research, and the associated industry version of capacity building. Their con-
cerns addressed questions of ethics and how to provide social justice for research
participants and patients as well for India as a nation. Their eﬀorts to promote
human rights protection for research subjects contributed to a drop in the
numbers of international trials coming to India. The case highlights how
health social movements could resist international clinical trials and mobilise
in ways that resulted in increased ethical oversight by governmental regulatory
structures (see also Heitmeyer, 2016) and demonstrates that a critical mass can
inﬂuence the working conditions of the pharmaceutical industry.
Analytical Perspectives
Voices of Indian activists and public health scholars need to be understood
against the backdrop of the emergence of RCTs as the gold standard of clinical
research globally, and its international critiques (Cooper, 2011; Timmermans
and Berg, 2010; Wahlberg and McGoey, 2007). Increasingly, this design, with
its ‘core set of methodologies – randomisation, blinding, clinical equipoise,
and informed consent that underpin the claims to universality that aim to
expunge uncertainty in clinical practice’ (Kelly, 2008, p. 102), is used across a
wide range of systems of knowledge production, disciplines and sectors, from
medicine and agriculture to education and economic development. Supporters
of the paradigm argue that judging what works should be based on eﬃcacious
interventions and good quality data rather than authority, tradition or politics.
Rather than simply being ‘pure and rational,’ however, RCTs have been cri-
ticised for trying to keep at bay the ‘messy stuﬀ’ and side-line other kinds of
knowledge (Simpson and Sariola, 2012). The RCT methodology has also
evolved in response to pressure from the public. Steven Epstein (1996) describes
how in the 1980s, LGBTIQ activists and study populations pushed back against
US trial regulations that prevented HIV+ people being included in early anti-ret-
roviral (ARV) studies. Activist groups criticised the US Food and Drug Admin-
istration (USFDA) regulations for being too rigid and slow in their operations.
By lobbying for changes in the inclusion and exclusion criteria of ARV trials,
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activists shaped how clinical trials have since been conducted and points to how
CSOs can actively inﬂuence research regulation.
Since Epstein’s seminal work on health social movements, literature on civil
society involvement in health, well-being and medical research has developed.
Brown et al. (2004, p. 50) have produced a typology of these movements: (1)
those seeking equitable access to health care and improved provision of health
care services; (2) constituency-based movements addressing health inequalities
based on race, ethnicity, gender, class and/or sexuality diﬀerences; and (3) embo-
died health movements that address disease, disability or illness experience by
challenging science on aetiology, diagnosis, treatment and prevention. These
movements often have a ‘disease-base,’ i.e. they focus on conditions such as
HIV (e.g. Epstein, 1996; Schneider, 2002), breast cancer (Klawiter, 1999; 2002)
or women’s reproductive health (Murphy, 2012). Often, experience of the
illness or lack of recognition of a condition is turned into an identity-based
struggle (Brown et al., 2004). Rabeharisoa et al. (2014) show how some
patient organisations actively join the ‘quest for cure’ as co-producers of knowl-
edge, shifting the meaning of expertise. Health social movements have mobilised
around issues such as access to medicines in the global south (Treatment Action
Campaign in South Africa: Schneider, 2002), extended deﬁnitions of risk and
exposure (breast cancer, see Klawiter, 2002; tobacco, see Nathanson, 1999),
and validation from within scientiﬁc communities as in the case of complemen-
tary and alternative medicines (Hess, 2015).
Mobilising around clinical trials in the Indian context, however, does not ﬁt
easily into any one of these categories. In India, many health social movements
organised their activities within the framework of ‘rights-based’ approaches,
within conceptions of bioethics and social justice, and have focused on health
inequalities (especially, but not only, those based on gender). The Jan Swasthya
Abhiyan (JSA), an umbrella organisation of CSOs concerned with health advo-
cacy in India, sees its role in terms of drawing attention to the eﬀects of ‘iniqui-
tous globalization on the health of Indian people.’ It ‘locates the campaign to
confront commercialization of health care and to achieve “Health For All” by
establishing the Right to Health and Health Care.’1 Such ideas assume particular
salience because, since the liberalisation of the Indian economy, its public health
sector has undergone radical changes. Rolling back state services has prompted a
vigorous network of advocacy and activist groups – broadly understood as civil
society – to campaign for more, and more equitable, public services (Goswami
and Tandon, 2013, p. 645). Here we are concerned with civil society activism
which includes: ‘Campaigns and policy advocacy eﬀorts [that] focus on the
rights of the excluded [and] target negative consequences of rapid economic
growth and rise of the free market’ (Goswami and Tandon, 2013, p. 657).
Negative consequences of liberalisation are central to the critiques of clinical
trials in India by social scientists, activists, and ethicists alike. In academic dis-
cussions, Sunder Rajan (2005; 2010; 2017), Cooper and Waldby (2014), and
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Prasad (2009) have argued that the quest for proﬁt has led to structural violence
for Indian research participants and researchers whereby commercial interests
trump ethical interests (see also Fisher, 2013; Jeﬀery, 2018). More speciﬁcally,
Prasad (2009) and Sunder Rajan (2017) argue that in the neo-liberal mode,
the Indian government has created conditions where it is possible to capitalise
on sickness. White (2011) states that instead of focusing on consent as the
marker of the ethics of a particular trial, what should be of ethical concern is
why, how, and for which populations a drug, vaccine, etc. is made available. Nar-
rowly focusing on bioethical processes in the conduct of a trial – e.g. taking
informed consent – legitimises exploitative power, rather than ensures auton-
omous decision making (White, 2011; Fisher, 2013). Kamat (2014) elaborates
these debates further by arguing that clinical research in India should be
carried out on diseases that are prevalent in India, so that the drugs that are
tested are relevant to the populations where the tests take place, rather than
helpful for patients elsewhere.
Issues raised by the emergence of global trials in India identiﬁed by public
health and bioethics activists and academics are best understood through
reﬂection on the concept of social justice. Although an expansive and
broadly deﬁned term without an agreed deﬁnition, social justice is emerging
in STS literature as an object of analysis alongside bioethics. Reardon
(2013) argues that the concept of bioethics has gained more prominent atten-
tion through e.g. programmes on the Ethics, Legal and Social Implications of
science (ELSI) and the central role that bioethics plays in regulation of science
collaborations. While bioethics is deﬁned in narrow terms associated with
bureaucracy, audit cultures and legal accountability (Reardon, 2013, p. 180),
social justice is seen to address collective power (Benjamin, 2016). Reardon
(2013, p. 179) proposes that: ‘calls for social justice oﬀer a space for thinking
about others. They orient around the collective – around what can come
together, and what cannot and why.’
Although Reardon characterises bioethics as an institutional audit-type
approach that contrasts with social justice, other deﬁnitions can be found. For
example, rather than seeing a dichotomy between bioethics and social justice,
others have framed bioethics as incorporating ‘justice’ as one of its four founda-
tional principles: autonomy, justice, beneﬁcence, and non-maleﬁcence
(Beauchamp and Childress, 1989; Sen, 2009). In particular, justice can be used
to scrutinise the distribution of beneﬁts and burdens in research involving
human subjects as well as ensuring that people are treated equally (Belmont
Report, 1979).
Furthermore, bioethics itself can be conceptualised as a structured form of
normative reﬂection and discussion on ‘what is the right thing to do,’ rather
than simply a set of bureaucratic practices. Amartya Sen’s theory of social
justice (2009) has deliberation as a central concept. He develops John Rawls’s
notion of justice as fairness but insists that justice is not an abstract ideal but
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is achieved through practical reasoning that should be directed towards action
reducing injustice and advancing justice (2009, p. ix).
Sen’s theory is helpful for understanding the methods and demands of social
movements in India. Ruger (2004) argues that global public health institutions
and organisations can contribute to reasoned debates on how to implement
general principles (such as the ‘right to health’) and support greater empower-
ment in the health sector, built on more regulation overall, and the reform of
state and social institutions. By this deﬁnition, instead of being an individual
quality, health justice is realised in social and political arrangements (Venkata-
puram, 2011). The case study discussed below analyses the activities of health
social movements in India as ﬁghting for social justice through collective
action, and engaging in normative reasoning of the beneﬁts, burdens and equal-
ity of research.
Methodology
This paper arises from a project entitled ‘Biomedical and Health Experimen-
tation in South Asia,’ that mapped experimental clinical and public health
research in South Asia. The study had ethical clearance from the Ethics Commit-
tee of Anusandhan Trust, Mumbai, India; Colombo Medical Faculty, Sri Lanka;
Nepal Health Research Council; and the School of Social and Political Science,
University of Edinburgh. We investigated the experimental activity taking
place, and people’s views about emerging social forms as well as their
counter-critiques, in India, Sri Lanka and Nepal. We conducted 337 interviews,
148 of which were in India, 73 in Nepal, 80 in Sri Lanka, and the rest in the US
and UK. This paper refers only to pharmaceutical trials in India, which consti-
tute the vast majority of South Asian clinical trials. We interviewed principal and
co-investigators, staﬀ of CROs, sponsors, regulators, activists, ethics committee
members, and key informants drawn from across the spectrum of those
researching or commenting on clinical trial activities.
For this paper, we analyse the views of 25 academic public health and medical
researchers and health activists. Those who could be classiﬁed as both research-
ers/doctors and activists were part of nine diﬀerent non-governmental organis-
ations based across India. Interviewees were prominent in medical research
institutions as well as in organisations that have been active in health advocacy
such as Low Cost Standard Therapeutics (LOCOST), Sama Resource Group for
Women and Children (SAMA), the Forum for Medical Ethics Society, members
of the Medico Friend Circle, and Jan Swasthya Abbhiyan. While not all the inter-
viewees would have thought of themselves as being part of a ‘social movement,’
they contributed to the discussions about the arrival of global trials. This
suggests that the critiques of international clinical trials went beyond activist
networks.
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The interviews were conducted in 2011 as the public discussion about clinical
trials intensiﬁed. We were part of the networks and our early reﬂections on the
project ﬁndings fed into the public debates at several conferences and national
hearings. Since the formal interviews were conducted, we have maintained infor-
mal contact with key activists, and have engaged in close readings of relevant
policy documents and publications.
We obtained written informed consent from participants. Interviewees were
provided with information sheets regarding the study and its aims. Interviews
were in English, recorded, transcribed, anonymised, and coded using Atlas.ti.
Transcripts were coded with regular checks for consistency. Codes relevant to
this paper include: ‘ethics,’ ‘knowledge production,’ ‘innovation,’ ‘new social
forms,’ ‘regulation and governance’ and ‘collaboration.’ The ‘ethics’ coding
included any discussions of cultural diﬀerences over ethical codes, malpractices
or scandals mentioned, post-trial access to drugs as an ethical issue, consent pro-
cedures and their value, and altruism as a way of engaging patients or use of
doctor–patient relationship to get consent or recruit patients. We also included
discussions of ethics review committees: perceptions of their competence, the
burden of work, the political pressures they work under, any conﬂicts of interest
and how they were resolved. Any mentions of injury and compensation for trial
participants, adverse event reporting as an ethical issue, insurance for trial par-
ticipants and for trial staﬀ, ‘guinea pig’ as a concept and the ethics of standards of
care or ancillary care for trial participants were also identiﬁed.
Issues of ‘fairness’ were raised in many of the quotations retrieved following
this approach, especially over post-trial access to drugs, and compensation for
adverse events. Dominant themes within each category were identiﬁed by
close reading and re-reading; quotations have been cited where they best exem-
plify the emergent perspectives. Some quotations have been edited for clarity.
The following sections are organised under key themes that emerged from the
review of the interviews: capacity building; commercialisation; and subaltern
voices and regulatory changes. For context, we provide a table compiled from
the website of the Indian government drug regulatory authority, CDSCO, of
trial approvals per year, 2007–2017 (Table 1).
Clinical Trials and Capacity Development
The Indian government and the pharmaceutical industry claimed that clinical
trials deregulation in 2005 would increase collaboration with the international
pharmaceutical sector and bring in skills and foreign investment. It was believed
that being part of a new research culture would provide its participants with cul-
tural and symbolic capital, which could be transformed into other forms of
capital, social and economic, such as networks, salaries, and international pos-
itions. Indian activists and researchers recognised that local motivations to col-
laborate are important but pointed out that ‘capacity to do what?’, remained a
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loaded question. Several of our interviewees saw that those who were working in
institutions drawn into collaborations with Big Pharma, CROs, study site hospi-
tals, etc. – at times their colleagues –were providing relatively unskilled labour to
produce global data rather than becoming innovators. When asked about what
kind of capacity was being built by the new research culture, a dean of medicine
and a public health researcher answered as follows:
It builds capacity in terms of making people understand the process – consenting, ran-
domisation, recruiting subjects, strategies around that – and that is some capacity
building. The problem with industry driven studies is that the protocol is written by
someone else, and you’re just an implementing agency. You don’t understand the
nitty-gritty of writing a protocol, doing research, [and] asking the questions yourself.
(Academic public health researcher 2011)
Other interviewees were also concerned that skills drawn together around clini-
cal trials replicated global hierarchies, and interviewees – explicitly or implicitly
— highlighted social injustices. They were critical of the direction in which the
industry was pushing clinical research and were attentive to power relations in
such collaborations. They saw Southern partners being left with handmaiden
roles as facilitators rather than as knowledge leaders. Another eminent
researcher attached to a university department in public health described clinical
trials research as follows:
Academics have started to shape themselves based on clinical trials, which is really pre-
cooked research, it is not research, it is operations, and I think it is a dreadful thing that
has happened to India. India is becoming a service centre-economy for the middle
class, extending to academics and research. (Academic public health researcher 2011)
This interviewee criticised what could be likened to the ‘coolie’ (a pan-Indian
term for precarious day labourers) role in clinical research and how Indian aca-
demics were reduced to servicing a research industry not driven by scientiﬁc
questions set locally but conforming to pre-deﬁned research questions set in –
and beneﬁting – the global North.
A retired senior researcher in public health drew an analogy between Indian
trials research culture and the outsourcing of oﬃce cleaning, suggesting that staﬀ
in janitorial companies can never progress beyond managing other janitors
according to externally generated rules:
There is a striking resemblance in what clinical trials are doing and what these guys are
doing. We are building a bunch of servants with diﬀerent capabilities but none of them
will ever come into the leadership role. (Academic public health researcher 2011)
Another researcher and sponsor, part of a national public health research organ-
isation that conducted cluster randomised public health interventions, elabo-
rated on this idea, suggesting that Indian researchers could break the glass
ceiling in international collaboration but, based on his/her long-term experience,
this took much longer than was reasonable:
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At the beginning, impact evaluations were all northern academic driven. Southern par-
ticipants were really just data collectors. Then, after doing some 300 projects the young
southern researchers have also matured and are sort of taking on leadership. But it
doesn’t need to take 10 years for that to happen. (Academic public health researcher
2011)
Themove towards clinical trialswas seen to be developing commercial rather than
scientiﬁc research capacity. Interviewees’ views resembled those of Melinda
Cooper (2011), for instance, who has argued that a clinical trial is essentially
not ‘research,’ but is more aptly described as a test, the result of which simply vali-
dated a prior set of ﬁndings or assumptions. Interviewees described power differ-
ences in the emerging research networks where existing capacities were oriented
to carrying out peripheral tasks in the CRO sector. They could be members in a
global science network but could not move towards being more central to knowl-
edge production. The high-powered roles of Indian biotech staff returning from
US or UK to run these networks were not mentioned as evidence to the contrary.
In the next section, we elaborate further on social justice-related concerns regard-
ing the commercialisation of research cultures.
Commercialisation of Research
Leading members of Indian CSOs did not see industry-driven R&D and increas-
ing commercialisation favourably. Commercialisation, they said, had a corrupt-
ing eﬀect. An academic researcher actively involved in public–private
partnerships with Big Pharma using RCTs described the institutional challenges
of trying to collaborate in a ﬁeld where certain sponsors can pay signiﬁcantly
higher fees to their investigators:
In the early days, many institutions were getting to know drug trials, particularly
company- sponsored drug trials. They realised that they are a good source of
income. So that was a big challenge that aﬀected us, being an academic centre. With
more than half of our studies with minimal or even very tight funding, it became a
challenge for us to match the expectations of those kinds of funding. How did
diﬀerent institutions respond to this? Two ways: one, ‘here’s an opportunity for us
to do good quality collaborative research!’ But the moment people began to see
money in this, then, two, it turned a little bit the wrong way, wherein money and
power came into the forefront, and research and science took the backseat. (Academic
researcher involved in commercial research 2011)
Academic researchers saw that increasing amounts of money in the hands of
researchers lured good PIs away from academic research. It was difﬁcult to
compete with promises made by commercial sponsors. Non-applied academic
research questions could become side-lined because they lacked monetary
potential. Academic freedom and basic ‘science for science’s sake’ were at
stake. Scientists had concerns about academic freedom and non-commercially
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viable research, in the face of the lure of ﬁnancial gain, reﬂecting age-old con-
cerns between academic research and industry.
To guarantee national interests in this climate was not straightforward. Here
the responses reﬂect the complexities of the changing pharmaceutical landscape.
One interviewee described the changes in research culture from the perspective of
the healthmovement that s/he was part of. Since 1978 they hadmaintained public
discussions regarding the global architecture of health politics and economics,
including e.g. intellectual property rights, generic pharmaceuticals and the priva-
tisation of science and technology infrastructures. They aimed at de-mystifying
science and technology to enable people’s participation in discussions about
health policy-making:
Looking at India, the issue of clinical trials brings forth both questions of the poten-
tial of science and what it can do for you, but also more importantly especially in
the Indian context the way scientiﬁc research today requires much larger societal
oversight and control in a situation where it’s becoming more and more complex.
So in that sense it’s becoming more and more diﬃcult for the public to grasp
what’s happening and be able to make sense of how they need to react to this.
(Doctor and science activist 2011)
Biomedical research has the potential for furthering public interests, then, but
commercialisation brings in complexities that were difﬁcult to grasp and
govern. For instance, commercial researchers could not guarantee that new
knowledge and research beneﬁts would stay in the country when such research
was aimed at global markets. Activists were largely correct in this regard. In a
study of 224 trials with an Indian site listed on clinicaltrials.gov in 2010, 133
did not result in marketing approval in India or the EU/USA (i.e. they failed).
Of the 91 that succeeded, 55 drugs were approved for sale in India, leaving 36
drugs approved in the EU or USA but not in India. This happened despite the
Indian drug regulatory authority’s requirement that sponsors guarantee that
they will market the drug in India after conducting a trial involving Indian partici-
pants (Limaye et al., 2015). Moreover, many drugs that are made available in India
remain too expensive for the poor (Nadimpally et al., 2016).
These discrepancies have led Medico Friend Circle, to which many of our
respondents belong, to argue in their mission statement that:
We believe that medical and health care must be available to everyone irrespective of
her/his ability to pay … Also that medical intervention and health care be strictly
guided by the needs of our people and not by commercial interests. We, therefore,
work towards health care services based upon human values, concern for human
needs, equality and democratic functioning.2
The statement highlights their concern about the commercialisation of health and
their embracing of the idea that the cost of a drug should not determine access to
medicines: this should be a matter of human rights. A further example of resist-
ance to the revenue-based pharmaceutical ﬁeld is LOCOST, a non-proﬁt
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charitable trust established in 1983 to provide drugs in pro-poor ways. Iyer (2012)
explains that LOCOST’s goal was to demonstrate that quality drugs can be pro-
vided at affordable prices, by making generic formulations and distributing
them via local social service organisations. One of the founder trustees stated
their principles – to ensure equitable access to medicines:
We don’t sell drugs in the main market. We started this organisation because a lot of
friends working in remote rural areas work with very poor people. They didn’t have
access to good quality medicines at reasonable prices, so we started with that. There
was a lot of demand. (Drug developer and activist 2011)
LOCOST does not conduct clinical trials. In a conversation regarding research
ethics, the interviewee illustrated the argument of this paper poignantly by
stating that RCTs are important but raise ethical problems.
Obviously, we need clinical trials. I really don’t have any alternatives in mind in terms
of advancement of knowledge, validation of knowledge and placebo control, double-
blind clinical trials or comparative trials. It raises a lot of problems but even with all
these problems it is still the best way there is to validate the statement. So you can’t
really throw the baby out with the bathwater. But there are ethical issues, we need
to think of the ethical mineﬁelds in these processes. Pharmaceutical companies and
especially contract research organisations in India are notorious for lacking ethical
oversight if nobody is looking. (Drug developer and activist, 2011)
Rather than denying the value of RCTs, the interviewee reﬂected on the ethical
problems and then suggested further points of regulation, some of which were
included in the 2013 legislation.
So we need a lot of regulatory oversight on ethical issues where clinical trials are con-
ducted, by which I mean four principles. First is accountability, if anything goes wrong
or goes right; second is transparency as far as possible. I agree that there are some
things called trade secrets, but I am not asking about trade secrets. If something goes
wrong, I shouldbe able to have enoughdata to place responsibility. The third thing is liab-
ility, there should be a lawof liability statingwho all should be accountable; that should be
very clear. And fourth is: I feel that our people in India, and especially poor people and
tribals, who are often the clinical targets in India, are easy targets. They need to be given
special care by the government and we need to have systems in place so that they are not
exploited. If anything goes wrong, they need to get compensation. We don’t have that
kind of regulatory system. We don’t have the resources to do research perfectly. As far
as ethics is concerned we are not very evolved. (Drug developer and activist, 2011)
On the one hand, LOCOST directly questions the underlying structures of
private pharmaceutical companies, such as patents, intellectual property, and
high prices of drugs that result from expensive research and hyperbolic claims
of their efﬁcacy. On the other hand, the interviewee criticises the Indian regulat-
ory framework in place prior to 2013, where the vulnerability of certain popu-
lations was exposed. S/he proposed amended regulation to prevent poor and
disenfranchised people being taken advantage of. There was no questioning of
the system of knowledge production through the RCT as such. On the contrary,
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the interviewee suggested that – despite the commercialised use of RCTs by Big
Pharma – structured comparison remains the best method to test if something
works, but that in India, more stringent regulation was needed.
Another public health researcher, who conducts evaluation and implemen-
tation studies and runs an NGO supporting health care access and rural health
development, also emphasised the interests of the public sector and people’s
access to health care. In a resolute statement, s/he illustrated a common feeling
that CSOs needed to do something about the regulatory situation:
I think we have to be in the real world, so I don’t think we can take a very ideological
and deterministic position, which we do and which I myself have taken in the past. My
feeling is that it is very important that the public interest has to be strengthened. Even
though I have strong reservations for all these public-private partnerships, my overall
feeling is that we must increase the stewardship and regulation of the government and
not just see it as regulation but to try and promote the public interest which is what the
government has been voted to do. So in that sense, I’m a little bit less deterministic
than I used to be. If you had asked me ten years ago, I might have said all research
should be done by the Indian Council of Medical Research, but I realise that the
way the world is going today you are going to have industry, you are going to have
R&D, and one has to regulate it. I don’t think just the legal approach helps. We also
need to strengthen professional leadership and equity, patients’ rights, patient’s char-
ters and things like that. So again, I think it is a question of being in dialogue and
ensuring that the public interest, safety, and equity, are raised, rather than only
talking about the source of funding. (Public health researcher and activist 2011)
The private sector has shown greater commitment to generic drugs than the
public sector, s/he said, to ensure that poorer Indian and global populations
could access drugs and health care, such as the cheap ARV therapies marketed
by CIPLA, an Indian commercial, generics pharmaceutical company. CSOs lob-
bying for change were struggling with these contradictions and the interviewee
proposed that simple ‘good/bad’ dichotomies were no longer useful or accurate.
In this context, drawing conclusions based on the origin of funding (private-bad
vs. public-good, or Indian-good vs. foreign-bad) no longer worked.
Like other interviewees, s/he said that local sacriﬁces should be clearly out-
weighed by local advantages. Balancing local interests was diﬃcult as Indian
ownership was no longer suﬃcient to ensure that beneﬁts were provided
locally. Nor was it always clear how international collaborations, foreign spon-
sors and private eﬀorts undermined national beneﬁt, or who could be trusted to
direct research in morally acceptable ways. For these interviewees, it was no
longer clear what national beneﬁt meant, nor how it could be guaranteed.
All this called for dialogue between civil society and the state, and consider-
ation of the ethics of the new situation. Despite the overall resistance to the com-
mercial pharmaceutical sector, the members of CSOs recognised that these trials
had come to stay, and that strategies were needed to improve regulation. In sum,
the question of the terms and conditions within which clinical trials should be
carried out did not lead to a call for refashioning of RCTs or, more broadly,
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evidence-based medicine. Rather, the new, commercialised situation required
new ethical considerations and regulatory frameworks. In less than ideal circum-
stances, members of civil societies put their dislike of global trials to one side in
order to ﬁnd a compromise that involved tighter regulation of the emerging
research to ensure rights of research participants.
Subaltern Voices and Regulatory Changes
CSOs engaged with research ethics in India highlighted lacunae in the regulation
and practice of clinical trials in place after the deregulation of trials in 2005.3 We
ﬁnish this paper with a meta-critique presented by one of the researchers who
linked global clinical trials with post-colonial relations in technoscience,
which elsewhere has been described as neo-colonialist (Nundy and Gulhati,
2005). His/her reﬂection poignantly describes how global tensions with the
pharmaceutical industry impact on participants and advocacy groups. Before
the new regulations were in place, s/he described anger among CSOs:
There is the basic reality in communities that people have been perceived to have been
coerced (into research) and they did die (as a result). This is such an insistent reality
that I understand why outrage alone seems to take centre-stage and why the outcome
feels like a rejection of trials. Subaltern voices are not heard, by and large, that’s what
we mean by them being subaltern voices, and so that when they are heard they will be
sweepingly stated. When you’re not heard, on the rare occasion on which you manage
to be heard, you will not sound nuanced and comprehensively aware of the many
aspects of the situation. Still less will you be enthusiastic (about) establishing a reason-
able dialogue because, really, you’re using that one rare opportunity simply to be heard
in protest. I cannot bring myself to say to people who are protesting about clinical
trials, that they shouldn’t be doing this, I cannot: it’s almost an emergent property
of the situation. So, yes, a strident rejection (of international RCTs) doesn’t do the
problem a great deal of practical solution but it is well-merited and understandable,
so I tend to want to say that they might use the strength of the outrage to make struc-
tural changes. It’s an old left strategy that doesn’t necessarily work but since I don’t
have anything better … . (Biomedical researcher and activist 2011)
The interviewee portrays the subaltern voices – the multiple voices of public
health researchers and health activists in India – shouting to be heard in
outrage. The anger was palpable in the public meetings organised by the activists
that we attended. But in more measured terms, CSOs’ strategic arguments have
helped bring about change. A persistent critique has been that the planning and
justiﬁcation by the Indian government for the deregulation of clinical trials made
little mention of beneﬁts to patients or populations; rather, foreign investment
and collaboration were foregrounded (Bajpai, 2013). Various arguments have
been raised around particular studies such as the demonstration project (or a
Phase IV trial – accounts differ) involving vaccination against Human Papilloma
Virus, starting in 2007, amongst 9–15-year-old girls in Andhra Pradesh and
Gujarat, many of whom were living in hostels and whose wardens gave mass
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consent (Parliament of India, 2013). Another set of problematic trials took place
between 2004 and 2008, when patients at the Bhopal Hospital for victims of the
gas leak disaster of 1984 were involved in trials, often without their knowledge
(Lakhani, 2011). A 2012 Parliamentary Report initiated by civil society groups
brought the ethical concerns to wider public notice and set in train reforms to
the procedures for the approval of clinical trials nationally (Parliament of
India, 2012).
Many activists and researchers we interviewed felt that lax regulations prior to
2013 were an invitation for international pharmaceutical companies to establish
their operations in India and that the government oﬃce that approves these
studies was ill-equipped to regulate them. The relaxed regulatory environment
and lack of emphasis on the rights of participants led a medical researcher
and social worker to elaborate on ethical variability (see also Petryna, 2009):
Now, I think one ethical issue in this is that when you have international collaboration,
how many international collaborators are collaborating with India because the ethical
guidelines and controls are much less? So in a way, in my general feeling, though it
might be a sweeping statement, a lot of international collaborations are ﬁnding surro-
gate partners in developing countries and are often not aware of the local levels of
ethical regulation. (Medical researcher and social worker 2011)
The reduction in the number of international trials in India post-2013 indicates
that this ﬂexibility had indeed encouraged companies to outsource their activi-
ties to India. A common concern of activists was that private ethics committees
acted as rubber-stamps for international (or local) pharmaceutical companies
(see also Simpson et al., 2015). Our interviewees accused ethics committees
assigned the role of reviewing clinical trials of having become money-minded,
when their role should be to protect vulnerable populations and defend the
interests of the Indian nation.
In the climate of lax ethical regulation of trials, one of the NGOs involved,
SAMA, describes its reasons for being involved in the campaign for the rights
of clinical trial participants as follows:
Biomedical research such as clinical trials are ﬁlled with many complex ethical issues,
which includes quality of health care, post-trial access to medicines for research par-
ticipants as well as general population, improper compensation mechanism in any
incident of trial related injury etc. With the growing number of clinical trials in
India, there have been many examples of clinical trials that have taken place with dis-
regard to ethical aspects and participants’ rights. There exists a striking lack of trans-
parency at the levels of planning, design and implementation of these trials. In the
absence of adequate regulatory jurisdiction and systematic review of the industry,
the reliability and validity of drug research in the country is jeopardized. SAMA is con-
sidering health a fundamental human right, and advocates for a rights-based approach
to health care for trial participants.4
The actions taken by the CSOs to inﬂuence government procedures included
several PIL petitions, notably by NGOs Swasthya Adhikar Manch (SAM) over
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irregularities in Bhopal, and by SAMA, Drug Action Forum, and Delhi Science
Forum over the HPV vaccine. Derived in part from US experience, in India PIL
petitions have been used since the 1970s to institute actions around environ-
mental, social and health issues, with differing effects (for more details, see
Divan, 2016; Terwindt, 2014). The judicial interventions that CSOs could
induce led to various ways of tightening the regulation of clinical trials registered
with the Government of India’s trial registry.5
In February 2013, under an amendment to Schedule Y of the Drugs and Cos-
metics Act, 1945, the Ministry of Health and Family Welfare required all ethics
committees to be registered with the Drugs Controller General India (DCGI)
before reviewing and approving a clinical trial. This order set out conditions
for ethical review, the composition of ethics committees, and mechanisms to
prevent conﬂicts of interest. Other rules dealt with documentation and com-
munications, conﬁdentiality and the maintenance of records to allow for inves-
tigations following adverse events. The possibility for trials to ‘shop around’ for
more pliable ethics committees has been at least partially addressed through the
centralised registration of ERCs. In registering a trial, sponsors must report all
applications for ethical review (Central Drug Standard Control Organization,
2013).
Major concerns among the interviewees included ‘informed consent,’ and its
implications for access to health care. A doctor and science activist weighed the
importance of trials to medical knowledge production with access to health as
follows:
For me the major ethical problem in having so many clinical trials in India … I’m not
against having clinical trials in India. As a science activist I won’t argue that you don’t
need clinical trials… But for me the biggest problem of clinical trials in India is related
to the public health system. The fact is that a majority of people are in a situation where
clinical trials oﬀer them the only way in which they can access treatment. I think that
goes against the notion of informed consent. But for me that is entirely meaningless
because even then there is a major element of coercion because of the systemic
reasons to do with the fact that the person is denied health care by the public
system, which forces him to enrol. (Doctor and science activist 2011)
Civil society groups lobbied for the inclusion of audio-visual recording of the
informed consent process, and a draft rule was published that would make
this compulsory for all clinical trial participants. This rule was later watered
down by limiting the audio-video requirement to the enrolment of ‘vulnerable’
patients/participants in clinical trials using New Chemical Entities or New Mol-
ecular Entities. What must be said to trial participants has been more clearly
speciﬁed, including (if it is a placebo-controlled trial) that the placebo will not
have any therapeutic value.
The most contentious aspect to the reforms has been the payment of compen-
sation for clinical trial-related injuries or death. The reforms aimed to clarify the
procedures for assessing clinical trial related injuries and deaths, and to ensure
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that appropriate compensation is paid to participants or their heirs and beneﬁ-
ciaries. However, uncertainties remain about the scope and extent of legal liab-
ility and how new rules might be implemented (Srinivasan, 2015).
Heightened standards of rights protection for trial subjects, such as higher
levels of compensation for injury and post-trial access to medicines, can increase
the costs of running a trial. Compensation in case of injury was stipulated in the
new legislation, while obligatory access to medicines was not. There is evidence
to suggest that the reason why obligatory post-trial access was dropped from the
new legislation had to do with the practical implications that access to medicines
would have on increasing costs to sponsors and CROs (Porter, 2017). Such costs
were feared to make India too expensive and thus a less attractive site for clinical
trials. Post-trial access remains a recommendation in the guidelines but is at the
discretion of sponsors and CROs. Activists have nonetheless continued to lobby
for the importance of post-trial access, especially to enhance the well-being of
poor populations in India (Nadimpally et al., 2016).
As a result of the regulatory changes, the number of clinical trials approved by
CDSCO dropped by a third in 2011–2012 from the ﬁgure for 2010 (see Table 1).
As Burt et al. (2014) also argue, the main contributory factor was the spotlight
that activists and the media directed towards clinical trials in India. With the
new legislation in 2013, approvals plummeted to a ﬁfth of what they were at
their peak in 2010. Several international companies, including the American
CRO Quintiles and AstraZeneca, closed units in Hyderabad and Bangalore.
Faced with these threats to the trials industry, the Drugs Controller General
of India suggested some easing of the proposals and also announced that a short-
ening of the time-frame for approval of new clinical trials to six months from
their submission.6
In sum, civil society groups were key to raising ethical concerns regarding
global RCTs and bringing attention to how clinical trials were conducted in
India. The public discussion about experimentation and novel modes of regu-
lation followed a vibrant social debate and a government-civil society dialogue.
CSOs successfully highlighted ethical issues and questions of social justice, pro-
tection of participants and opposition to exploitation that went beyond the pre-
vious tick-box approach to ethical assessment. They highlighted controversial
trials to leverage public attention and politicised them by bringing them to
the attention of the Indian Parliament. Using tools such as blogs, publications
and the PIL, CSOs’ members insisted on discussions of social and moral
values. Their use of ethics and patient rights was a rhetorical tactic to counter
industry arguments and pushed the government to take action to regulate
better the clinical trials taking place in the country. They maintained strategic
attention on public interests and prevention of exploitation while ensuring
that lines of communication stayed open. Rather than a demand to ban all clini-
cal trials, as a couple of activists in private told us they would prefer, it is likely
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that this active engagement worked much better as a strategy to change
regulation.
Theirs was not a call for scientiﬁc pluralism, however, or a wholesale denial of
clinical research methodologies. Researchers and activists supported controlled
experimentation as a methodology and saw comparison as a scientiﬁc gold stan-
dard. Perhaps because of their non-fundamentalist stance and the language of
medical research that they shared with their interlocutors in the industry and
in government, they were able to develop a coherent strategy to bring clinical
trials under more regulation. Thus they were able to craft an alternative direction
to the clinical trials industry by global and local pharmaceutical companies in
India.
Conclusion
In this paper we have described the ethical deliberation and action taken by
CSOs in India in response to the increase of international clinical trials after
2005. Unlike other academic observers of international clinical trials in India,
we have focused not on the exploitative dimensions of the increase, but rather
on CSOs’ activities challenging the views of the clinical trials industry and gov-
ernment regulators. CSOs played a major role in changing research regulations
in 2013, in turn leading to a decline in clinical trials in the country.7
Their success marks a noteworthy example of action against neo-liberal
pharmaceutical regimes. CSOs raised issues about access to medicines, problems
in ethical regulation, and the overall commercialisation of research within
unequal collaborative structures. The new regulations directly addressed
CSOs’ concerns regarding ethical oversight and slowed down (at least tempor-
arily) the trend towards commercialising research.
The example stands out among health social movements in two distinct ways.
Unlike much of the past literature on health social movements, the activism
against global trials in India did not come from identity or illness-based move-
ments of patient activists (Rabeharisoa et al., 2014). Nor were our interviewees
lay people engaged by Global Health sponsors or policy-makers (Reynolds and
Sariola, 2018). Rather the Indian CSOs were a diverse group of medical pro-
fessionals who often ran humanitarian eﬀorts alongside their academic or clini-
cal practices. Although they were critical of the social justice implications of
trials, they shared central notions regarding the RCT methodology with the
industry conducting trials and those who were governing them, i.e. the govern-
ment body in charge of national research regulations.
CSO action criticised how the global pharmaceutical industry was pushing the
ﬁeld of biomedical research towards commercial testing, thus undermining a
socialist pharmaceutical sector with a vibrant generics industry that previously
had made cheap drugs available for the masses (Sunder Rajan, 2010; Sariola
et al., 2015). This shift towards commercialisation, they thought, created and
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recreated global injustices for research participants and researchers alike.
Especially for those with a strong Marxist, humanitarian, or social work ethos,
commercialisation was seen to be taking the ﬁeld of medical research in the
wrong direction.
While Indian CSOs did not want to ‘Stop the march of knowledge,’ as sum-
marised by one of our interviewees in 2011, they did redirect clinical trial activity
in the country. CSOs in India were successful in shaping research regulation,
partly because they shared the language and principles of research methodology
with government innovation policy-makers and the clinical trials industry.
Unlike resistance to RCTs as hegemonic forms of knowledge production, as
expressed in the STS literature and other articles in this special issue, Indian acti-
vists had conﬁdence in RCTs as a method. Industry, government and our inter-
viewees saw comparative methods as central to deﬁning what works; they valued
what medical research can deliver.
Despite the methodological overlaps, however, the CSOs emphasised wider
ethical concerns that speciﬁcally aﬀect low-income populations, facing an Indian
government that has been strongly pro-industry since 2014. When CSOs used
various strategies such as PIL to put pressure on the government to change research
regulation, they sought to enact social justice through public reasoning and action,
as in the strategy proposed by Amartya Sen (2009). Embodying this pragmatic
account of justice through their campaigning, CSOs lobbied the government to
change ethical guidelines concerning patient and participant rights, consent, and
compensation following injury or death. Indian CSOs were able to push for regu-
latory changes that addressed rights of trial participants on their own terms. With
an Indian government since 2014 that is strongly pro-industry and investment,
however, the battle for more equal relations in the industry is not over. On-going
ethical debate is needed to address the question raised in 2011 by an ethicist-acti-
vists who was concerned about national beneﬁt: ‘What’s in it for us?’
Notes
1. http://phmindia.org/about-us/ (accessed 15 September 2017).
2. http://www.mfcindia.org/main/perspective.html (accessed 15 September 2017).
3. Activists in India have commented on ethics of clinical trials before the 2005 deregula-
tion of international pharmaceutical companies: an early instance is the 1993 study in
Gadchiroli on alternative modes of providing neo-natal services, in which infants in
control groups did not receive best available alternative care (Angell, 2007; Bhutta,
2007). The ethical-technical details that were discussed around this study included
the deﬁnition of standard of care. How should control groups be chosen in very impo-
verished contexts where access to such best care is not available but when second best
options are being tested (Bandewar and John, 2011; see also Bang, 2010)? As in the
ARV trial scandals in Africa, purists argued that standard of care should be the
same everywhere irrespective of the sponsor, location and population, while pragma-
tists argued that somehow local realities need to be improved and that research is
needed for that (Haire, 2013; van der Vliet, 2004).
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4. http://www.samawomenshealth.in/ethics-in-clinical-trials/ (accessed 15 September 2017).
5. Much of the activity of CROs in India is concerned with bio-availability and bio-equiv-
alence trials, which largely escape such regulation. A window on how much work is
being carried out for producers of generic drugs is provided by the accusations of mal-
practice made against GVK Biosciences, in Hyderabad, which led to the withdrawal of
recognition by the European Medicines Agency of some 700 drugs made in India
(Sariola, 2015).
6. http://www.sgpgi.ac.in/sop/Action_RR_Choudhury_Committee__06.11.2013.pdf, p. 3
(accessed 14 September 2016).
7. For an analysis of another politicised health social movement in India see the motion
developed to free Binayak Sen, a doctor who worked in social medicine in Chhattis-
garh, a very impoverished tribal area, and was arrested for supporting a Maoist politi-
cal movement (Sinha, 2015). There were some overlaps in organisations that mobilised
against clinical trials and for freeing Binayak Sen.
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